TACE SURVIVAL DATA
THE EVIDENCE BASE
Two pivotal randomised trials in 2002 established TACE as the survival-extending standard for intermediate HCC. Two decades of subsequent evidence — including combination data with sorafenib, lenvatinib, and immunotherapy — have refined how TACE is used and for whom.
analyticsAt a Glance
- check_circleLlovet et al. (2002, Barcelona): TACE vs best supportive care — 2-year OS 63% vs 27% — trial stopped early for TACE benefit
- check_circleLo et al. (2002, Hong Kong): TACE vs conservative — median OS 26 vs 16 months
- check_circle2 meta-analyses (Llovet & Bruix 2003; Marelli et al. 2007) confirmed OS benefit across studies
- check_circleTACTICS trial: TACE + sorafenib vs TACE alone — PFS improvement; combinations now entering routine practice
The Evidence Base for TACE in HCC: A Structured Overview
Before 2002, there was no proven survival benefit for any treatment in patients with unresectable HCC beyond surgical resection. TACE was widely used but its benefit unproven. Two concurrent randomised controlled trials — published simultaneously in The Lancet in 2002 — changed this by demonstrating for the first time that a non-surgical treatment extended survival in this population.
“The Llovet and Lo trials did not just prove TACE works — they created the framework for evidence-based HCC oncology and established the standard against which all subsequent treatments have been compared.”
The Level 1 Evidence Foundation
Two independent RCTs — Barcelona (Llovet et al.) and Hong Kong (Lo et al.) — using different TACE protocols (Lipiodol cTACE in Barcelona; cisplatin DEB-like protocol in Hong Kong) both demonstrated significantly improved survival with TACE versus best supportive care or conservative management. The Barceló trial was stopped early by its ethics committee due to clear TACE benefit. Both studies enrolled Child-Pugh A–B patients with multinodular HCC.
Evolution of the Evidence: Combinations and Modern Series
Since 2002, the evidence base has expanded in two directions: (1) Combination trials adding systemic therapy to TACE — sorafenib (SPACE, TACTICS), lenvatinib, and checkpoint inhibitors (EMERALD-1 with durvalumab + TACE); (2) Comparative effectiveness data from large multicentre registries. The TACTICS trial (TACE + sorafenib vs TACE alone) showed improved PFS with combination — a landmark finding driving current practice.
Pivotal Trial Results: Survival Data
The following data from the two pivotal RCTs and the TACTICS combination trial represent the core evidence base for TACE in HCC.
Llovet et al. (2002) and Lo et al. (2002) — TACE vs Control
Llovet: Lancet 2002;359:1734–1739 (Barcelona). Lo: Lancet 2002;359:1729–1733 (Hong Kong). Both trials unresectable HCC; TACE = cTACE with Lipiodol/cisplatin
- 2-year OS: TACE arm (Llovet, Barcelona)63%
- 2-year OS: Control arm (Llovet, Barcelona)27%
- Median OS: TACE arm (Lo, Hong Kong)26 mo
- Median OS: Control arm (Lo, Hong Kong)11.5 mo
TACTICS Trial — TACE + Sorafenib vs TACE Alone (PFS Primary Endpoint)
Source: Kudo M et al., Gut. 2020;69(8):1492–1501. Superselective TACE; sorafenib started 2–3 weeks after TACE; Japan-only trial.
- Median PFS: TACE + Sorafenib25.2 mo
- Median PFS: TACE alone13.5 mo
- Time to TACE failure: TACE + Sorafenib26.7 mo
- Time to TACE failure: TACE alone20.6 mo
Key TACE Trials: A Reference Overview
A structured reference of the most important TACE clinical trials and their key contributions to the evidence base.
| Trial | Year | Design | n | Key Finding |
|---|---|---|---|---|
| Llovet et al. (Barcelona RCT) | 2002 | Phase III RCT: TACE vs embolisation vs best supportive care | 112 | TACE arm stopped early — 2-yr OS 63% vs 27% with BSC; established TACE survival benefit |
| Lo et al. (Hong Kong RCT) | 2002 | Phase III RCT: TACE (cisplatin) vs conservative management | 80 | TACE: median OS 26 mo vs 11.5 mo; landmark dual publication with Llovet establishing Level 1 evidence |
| Llovet & Bruix meta-analysis | 2003 | Meta-analysis of 7 RCTs including Llovet and Lo | 516 | Confirmed TACE significantly reduces 2-year mortality (OR 0.53) — key regulatory impact |
| PRECISION V | 2010 | Phase III RCT: DEB-TACE vs cTACE | 212 | Similar objective response; DEB-TACE less hepatotoxicity and systemic adverse events — established DEB-TACE as a valid alternative |
| SPACE trial | 2012 | Phase II: DEB-TACE + sorafenib vs DEB-TACE + placebo | 307 | No PFS improvement with sorafenib — largely negative; TACTICS later showed benefit with sequential approach |
| TACTICS trial | 2020 | Phase II RCT: TACE + sorafenib vs TACE alone (Japan) | 156 | PFS 25.2 vs 13.5 months — significant PFS benefit; sorafenib started 2–3 weeks post-TACE, not concurrently |
| EMERALD-1 (durvalumab + TACE) | 2024 | Phase III: DEB-TACE + durvalumab ± bevacizumab vs TACE | 616 | PFS significantly improved with durvalumab + bevacizumab + TACE vs TACE alone — first immunotherapy TACE combination with Phase III PFS benefit |
The Combination Era: TACE + Systemic Therapy
After decades as a standalone locoregional treatment, TACE is now being combined with systemic agents — sorafenib, lenvatinib, checkpoint inhibitors, and anti-angiogenic drugs — in a new generation of trials seeking to address TACE's key limitation: inability to prevent distant intrahepatic recurrence.
TACTICS: Why Sequential (Not Concurrent) TACE + Sorafenib Works
Multiple trials combining TACE with concurrent sorafenib failed (SPACE, TACE-2). The TACTICS trial showed benefit using a specific protocol: sorafenib started 2–3 weeks after TACE (not during) and continued until TACE unresponsiveness. The sequential approach allows TACE-induced necrosis to complete before sorafenib's anti-angiogenic effects suppress the collateral vessel growth that is essential for post-TACE liver recovery. This timing insight — sorafenib as a TACE adjuvant rather than a concurrent partner — changed how combinations are designed.
EMERALD-1: Immunotherapy Enters TACE
The EMERALD-1 trial (published 2024) demonstrated that DEB-TACE combined with durvalumab (anti-PD-L1) plus bevacizumab significantly improved progression-free survival compared to TACE alone. This is the first Phase III trial to show a PFS benefit for any immunotherapy-TACE combination — and is expected to change practice for appropriate BCLC B patients who are fit for systemic therapy alongside TACE.
What Combination Data Mean for Patients
The combination era means that BCLC B patients who are systemic therapy candidates (Child-Pugh A, ECOG 0) may benefit from TACE combined with sorafenib, lenvatinib, or immunotherapy — not TACE alone. At centres that adopt the TACTICS protocol or EMERALD-1 approach, the conversation about TACE eligibility increasingly includes a discussion about concurrent or sequential systemic therapy.
More from the TACE Resource Library
Continue exploring TACE — from technique selection and patient eligibility to transplant bridge applications.
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- TACE as Bridge to Liver Transplant: How It Works
- TACE Therapy — Complete Treatment Guide
- Sorafenib for Liver Cancer: Advanced HCC Treatment
Frequently Asked Questions
Common questions about the clinical evidence for TACE.
About TACE Evidence
If TACE was proven to work in 2002, why do some doctors still question its benefit?
The Llovet and Lo trials established TACE's survival benefit versus best supportive care — but several important caveats remain: (1) they enrolled selected patients, and the benefit does not automatically extend to all BCLC B patients; (2) techniques have evolved significantly since 2002 (cTACE with older protocols vs modern superselective DEB-TACE); (3) systemic therapies have improved substantially, raising the question of whether TACE should be combined with or replaced by systemic therapy in some patients. The PRODIGE 7 controversy in colon cancer HIPEC has a partial parallel here — TACE's survival benefit is well established for appropriate patients, but debate continues about optimal technique, patient selection, and combination strategies. This is a sign of an evolving field, not of the original evidence being invalid.
Should I be receiving sorafenib or lenvatinib alongside my TACE?
The TACTICS trial data support adding sorafenib to TACE in eligible patients — specifically using the sequential protocol (sorafenib started 2–3 weeks after TACE, not concurrently). EMERALD-1 data support durvalumab + bevacizumab alongside DEB-TACE. Whether you should receive combination is determined by: your Child-Pugh score (A preferred for systemic therapy), ECOG performance status, tumour characteristics, and whether you can tolerate the combined toxicity of TACE plus systemic therapy. For Child-Pugh A, ECOG 0, BCLC B patients — the combination approach is increasingly the discussion at specialist MDTs. For Child-Pugh B7 or ECOG 1 patients — TACE alone remains the appropriate starting point. Discuss this specifically at your hepatobiliary MDT review.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Reviewing Your TACE Treatment Options?
CancerFax can connect you with specialist hepatobiliary oncologists who review the latest TACE evidence and can advise on whether TACE alone, TACE + systemic therapy, or an alternative locoregional approach is most appropriate for your HCC stage and liver function.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.